Actin vs Elara Health and Wellness
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Elara Health and Wellness
Best for Patients seeking a physician-guided bundled-care GLP-1 program (medication + quarterly labs + physician visits + coaching + 24/7 messaging at a single monthly price) with maximum pharmacy-partner transparency (four named 503A pharmacies disclosed) and clear corporate accountability (JTE Medical, LLC named parent). Strong fit for buyers who want more than transactional Rx access but don't need the unlimited-primary-care scope of true DPC models.Starting at $117/mo
Side-by-Side Comparison
| Feature | Actin | Elara Health and Wellness |
|---|---|---|
| Overall Score | 7.0/10 | ✓8.2/10 |
| Starting Price | $133/mo | ✓$117/mo |
| Editorial Rating | 3.5 ★ /5 | ✓4.1 ★ /5 |
| Features | 2 features | ✓10 features |
| States Available | 0 | ✓51 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Elara Health and Wellness
Pros
- ✓Corporate parent explicitly disclosed (JTE Medical, LLC) — rare transparency for a DTC GLP-1 platform
- ✓FOUR named 503A pharmacy partners with city/state disclosure — among the most pharmacy-transparent providers in the WLR directory
- ✓Bundled care-team model (quarterly labs + physician visits + coaching + 24/7 messaging) is a fundamental differentiation from transactional DTC marketplaces — closer to a Direct Primary Care framing without the membership-fee structure
- ✓Verbatim FDA compounded-medication disclaimer published — meets the WLR transparency rule for 503A platforms
- ✓All 50 states + DC coverage with explicit framing (no vague 'most states' language)
- ✓Annual plan savings are substantial ($792/yr semaglutide, $858/yr tirzepatide) and competitive vs broader DTC market
- ✓Self-service cancellation on monthly/quarterly plans — no phone-call retention pressure
- ✓GLP-1 Support Pack add-on offers integrated supplement-stack option without bundling pressure
Cons
- ✗LegitScript certification status NOT disclosed publicly — recommend Edwin verify with provider directly
- ✗Named medical director / physician leadership NOT disclosed publicly
- ✗Annual plan requires 12-month commitment — early-cancellation terms not detailed in indexable content
- ✗Governing law / arbitration venue NOT disclosed publicly
- ✗503B option NOT offered — 503A patient-specific compounding only (which may be a limitation for patients seeking 503B bulk-compounded supply chain)
Our Verdict
Elara Health and Wellness edges out Actin with a higher overall score of 8.2/10 and is particularly strong for Patients seeking a physician-guided bundled-care GLP-1 program (medication + quarterly labs + physician visits + coaching + 24/7 messaging at a single monthly price) with maximum pharmacy-partner transparency (four named 503A pharmacies disclosed) and clear corporate accountability (JTE Medical, LLC named parent). Strong fit for buyers who want more than transactional Rx access but don't need the unlimited-primary-care scope of true DPC models.. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.